This company has been marked as potentially delisted and may not be actively trading. Vaccitech (VACC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesInsider TradesOwnershipTrendsBuy This Stock VACC vs. TNXP, ENTA, NLTX, TLSA, XBIT, OPTN, ZNTL, COYA, BHST, and ORMPShould you be buying Vaccitech stock or one of its competitors? The main competitors of Vaccitech include Tonix Pharmaceuticals (TNXP), Enanta Pharmaceuticals (ENTA), Neoleukin Therapeutics (NLTX), Tiziana Life Sciences (TLSA), XBiotech (XBIT), OptiNose (OPTN), Zentalis Pharmaceuticals (ZNTL), Coya Therapeutics (COYA), BioHarvest Sciences (BHST), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical preparations" industry. Vaccitech vs. Tonix Pharmaceuticals Enanta Pharmaceuticals Neoleukin Therapeutics Tiziana Life Sciences XBiotech OptiNose Zentalis Pharmaceuticals Coya Therapeutics BioHarvest Sciences Oramed Pharmaceuticals Tonix Pharmaceuticals (NASDAQ:TNXP) and Vaccitech (NASDAQ:VACC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, community ranking, dividends, media sentiment, valuation and earnings. Do insiders and institutionals hold more shares of TNXP or VACC? 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 26.1% of Vaccitech shares are held by institutional investors. 0.0% of Tonix Pharmaceuticals shares are held by insiders. Comparatively, 6.0% of Vaccitech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has better valuation & earnings, TNXP or VACC? Vaccitech has higher revenue and earnings than Tonix Pharmaceuticals. Vaccitech is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTonix Pharmaceuticals$10.09M10.02-$116.66M-$2.54 thousand-0.01Vaccitech$13.42M2.10$5.34M-$1.43-0.51 Does the MarketBeat Community favor TNXP or VACC? Tonix Pharmaceuticals received 324 more outperform votes than Vaccitech when rated by MarketBeat users. However, 70.83% of users gave Vaccitech an outperform vote while only 60.78% of users gave Tonix Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTonix PharmaceuticalsOutperform Votes34160.78% Underperform Votes22039.22% VaccitechOutperform Votes1770.83% Underperform Votes729.17% Do analysts rate TNXP or VACC? Tonix Pharmaceuticals currently has a consensus target price of $585.00, indicating a potential upside of 3,623.74%. Given Tonix Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Tonix Pharmaceuticals is more favorable than Vaccitech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Vaccitech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is TNXP or VACC more profitable? Vaccitech has a net margin of -409.18% compared to Tonix Pharmaceuticals' net margin of -1,197.86%. Vaccitech's return on equity of -23.41% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tonix Pharmaceuticals-1,197.86% -163.95% -118.88% Vaccitech -409.18%-23.41%-20.85% Which has more risk & volatility, TNXP or VACC? Tonix Pharmaceuticals has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Vaccitech has a beta of -0.4, indicating that its share price is 140% less volatile than the S&P 500. Does the media prefer TNXP or VACC? In the previous week, Tonix Pharmaceuticals had 1 more articles in the media than Vaccitech. MarketBeat recorded 1 mentions for Tonix Pharmaceuticals and 0 mentions for Vaccitech. Vaccitech's average media sentiment score of 0.00 beat Tonix Pharmaceuticals' score of -0.22 indicating that Vaccitech is being referred to more favorably in the news media. Company Overall Sentiment Tonix Pharmaceuticals Neutral Vaccitech Neutral SummaryTonix Pharmaceuticals and Vaccitech tied by winning 9 of the 18 factors compared between the two stocks. Get Vaccitech News Delivered to You Automatically Sign up to receive the latest news and ratings for VACC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VACC vs. The Competition Export to ExcelMetricVaccitechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.14M$6.45B$5.30B$7.35BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-0.516.8921.8017.80Price / Sales2.10231.03379.9697.74Price / Cash19.3065.6738.2634.64Price / Book0.115.936.443.98Net Income$5.34M$142.99M$3.21B$247.73M Vaccitech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VACCVaccitechN/A$0.73+3.5%N/A-72.9%$28.14M$13.42M-0.5133Gap UpTNXPTonix Pharmaceuticals2.3264 of 5 stars$15.91-6.4%$585.00+3,577.2%-96.9%$103.60M$10.09M0.0050ENTAEnanta Pharmaceuticals4.0354 of 5 stars$4.82-6.5%$17.25+258.3%-63.6%$102.93M$66.59M-0.97160NLTXNeoleukin TherapeuticsN/A$10.89-1.0%N/A-69.4%$102.34MN/A-3.5090Gap DownHigh Trading VolumeTLSATiziana Life Sciences0.6556 of 5 stars$0.87+6.9%N/A+108.6%$101.31MN/A0.008Gap DownXBITXBiotech0.8295 of 5 stars$3.05-4.1%N/A-63.7%$93.14M$4.01M-2.83100Positive NewsOPTNOptiNose3.2933 of 5 stars$9.20+0.1%$9.00-2.2%-40.1%$92.56M$78.23M-2.19190Short Interest ↓Positive NewsZNTLZentalis Pharmaceuticals2.0329 of 5 stars$1.28+0.4%$8.24+546.6%-89.9%$91.56M$67.43M-0.51160COYACoya Therapeutics2.4253 of 5 stars$5.45-1.2%$17.00+212.2%-36.2%$91.07M$3.55M-8.386Positive NewsBHSTBioHarvest SciencesN/A$5.50-1.8%$13.00+136.4%N/A$90.34M$25.19M-4.40N/APositive NewsORMPOramed Pharmaceuticals1.4834 of 5 stars$2.19-1.8%N/A-7.7%$89.46M$1.34M19.9110Gap Down Related Companies and Tools Related Companies Tonix Pharmaceuticals Competitors Enanta Pharmaceuticals Competitors Neoleukin Therapeutics Competitors Tiziana Life Sciences Competitors XBiotech Competitors OptiNose Competitors Zentalis Pharmaceuticals Competitors Coya Therapeutics Competitors BioHarvest Sciences Competitors Oramed Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VACC) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccitech plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccitech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VACC Stock Free VACC Stock Alerts